Nexalin Technology (NASDAQ:NXL) Trading Up 1% – What’s Next?

Nexalin Technology, Inc. (NASDAQ:NXL)’s share price rose 1% on Thursday . The company traded as high as $0.65 and last traded at $0.63. Approximately 53,433 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 157,195 shares. The stock had previously closed at $0.6238.

Wall Street Analysts Forecast Growth

NXL has been the subject of several recent research reports. Wall Street Zen downgraded shares of Nexalin Technology from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Nexalin Technology in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.00.

Nexalin Technology Price Performance

The firm has a market cap of $11.29 million, a price-to-earnings ratio of -0.92 and a beta of 3.94. The stock’s fifty day moving average price is $0.82 and its 200-day moving average price is $0.99.

Nexalin Technology (NASDAQ:NXL) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Nexalin Technology had a negative net margin of 5,527.39% and a negative return on equity of 207.46%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.04 million.

Institutional Trading of Nexalin Technology

A hedge fund recently bought a new stake in Nexalin Technology stock. Susquehanna International Group LLP bought a new position in Nexalin Technology, Inc. (NASDAQ:NXL) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 62,498 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned about 0.35% of Nexalin Technology as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.65% of the company’s stock.

Nexalin Technology Company Profile

Nexalin Technology, Inc is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S.